Supernus Pharmaceuticals reported $401.97M in Debt for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Ani Pharmaceuticals ANIP:US USD 286.52M 213K
Aurora Cannabis Inc ACB:CN CAD 226.08M 99.49M
Bristol Myers Squibb BMY:US USD 39.32B 222M
Canopy Growth Corp WEED:CN CAD 1.32B 158.19M
Eisai 4523:JP JPY 150.12B 55.21B
Endo International Ordinary Shares ENDP:US USD 1.42M 8.09B
Horizon Pharma HZNP:US USD 2.56B 2.3M
Lannett LCI:US USD 623.86M 4.51M
Marinus Pharmaceuticals MRNS:US USD 71.02M 238K
Pacira Pharmaceuticals PCRX:US USD 689.47M 58.4M
Perrigo Ordinary Shares PRGO:US USD 4.11B 4.4M
Revance Therapeutics RVNC:US USD 380.04M 8.24M
Supernus Pharmaceuticals SUPN:US USD 401.97M 530K
Teva Pharmaceutical Industries TEVA:US USD 21.21B 54M
United Therapeutics UTHR:US USD 800M 0
Xeris Pharmaceuticals Inc XERS:US USD 187.08M 48.57M